Source-grounded facts extracted from INTERPACE BIOSCIENCES, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2026 results: revenue $9.0 million, net income $0.8 million. Guidance reaffirmed.
“Interpace generated Q1 2026 revenue of $9.0 million on 12% year-over-year thyroid revenue growth, delivered $0.8 million of income from continuing operations”
INTERPACE BIOSCIENCES, INC. reported fourth quarter and fiscal year ended December 31, 2025 results: revenue $9.2 million and $38.7 million, respectively, net income $22.8 million and $25.0 million, respectively.
“stated in such filing. --- EX-99.1 (EX-99.1) --- Interpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business Results ● Q4 and FY Revenue of $9.2 million and $38.7 million ● Q4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment) ●”
INTERPACE BIOSCIENCES, INC. announced a restructuring with charges of severance costs in the range of $0.5 million to $0.6 million to be recorded primarily in the second quarter of 2025 which is in addition to the $0.2 million pre affecting workforce reduction (reducing its workforce).
“On April 25, 2025, the Company announced implementation of its previously approved restructuring and cost-savings plan to reduce operating costs and better align its workforce with the loss of PancraGEN® (the “Restructuring Plan”).”
INTERPACE BIOSCIENCES, INC. reported that prior financial statements should not be relied upon.
“t will be required to restate its previously issued financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as well as the financial statements contained in the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024 and March 31, 2023, June 30, 2024 and June 30, 2023, and September 30, 2024 and September 30, 2023 to effect reversals of accrued royalties expenses. Accordingly, investors should no longer rely upon such financial statements. The reversal of accrued royalties expense is a result of the Company’s determination that the accrual of such royalties expenses was not required. The reversal is expected to have a positive impact on various financial statement items, including current liabilities, stockholders’ equity (deficit) and net income. On February 28, 2025, the Company’s management conclud”
INTERPACE BIOSCIENCES, INC. announced a restructuring with charges of $0.8 million to $1.0 million affecting workforce related to PancraGEN® coverage loss (reducing its workforce).
“Plan, the Company is reducing its workforce and impacted employees will be eligible to receive severance benefits. The Company expects to incur severance costs in the range of $0.8 million to $1.0 million which will be recorded primarily in the first quarter of 2025. The substantial majority of the severance payments are expected to be made by the end of the second”
INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2024 results: revenue $10.3 million, net income $0.6 million.
“stated in such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces First Quarter 2024 Financial and Business Results ● Q1 Revenue of $10.3 million; a 4% increase year-over-year ● Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 9, 2024 (GLOBE NEWSWIRE) — Interpace Biosciences, Inc. (“Interpace” or”
INTERPACE BIOSCIENCES, INC. reported preliminary financial results for the fourth quarter and fiscal year ended December 31, 2023.
“On March 7, 2024, Interpace Biosciences, Inc. issued a press release announcing its preliminary results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023.”
Robert Gorman resigned as Director and Chairman at INTERPACE BIOSCIENCES, INC..
“On December 7, 2023, Robert Gorman, a Class II director designated by Ampersand 2018 Limited Partnership to the board of directors (the “ Board ”) of Interpace Biosciences, Inc. (the “ Company ”), provided notice to the Company of his resignation as a director and as Chairman of the Board, including as a member of the Board’s Regulatory Compliance Committee, effective immediately.”
INTERPACE BIOSCIENCES, INC. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-11-14 meeting.
“Ratification of the appointment of EisnerAmper, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023. For Against Abstain Broker Non-Vote 10,907,312 42,734 3,393 0”
INTERPACE BIOSCIENCES, INC. shareholders approved A non-binding advisory vote on the frequency of executive compensation advisory votes. at the 2023-11-14 meeting.
“A non-binding advisory vote on the frequency of executive compensation advisory votes. Every One Year Every Two Years Every Three Years Abstain Broker Non-Vote 202,362 10,069 9,089,392 35,746 1,615,870”
INTERPACE BIOSCIENCES, INC. shareholders approved A non-binding advisory vote on a resolution approving the compensation of our named executive officers. at the 2023-11-14 meeting.
“A non-binding advisory vote on a resolution approving the compensation of our named executive officers. For Against Abstain Broker Non-Vote 9,177,922 73,760 85,887 1,615,870”
INTERPACE BIOSCIENCES, INC. shareholders approved Election of two Class III directors to serve until the 2026 annual meeting or until each such director's successor is duly elected and qualified. at the 2023-11-14 meeting.
“Election of two Class III directors to serve until the 2026 annual meeting or until each such director's successor is duly elected and qualified. Name For Withhold Broker Non-Vote Thomas W. Burnell 9,294,768 42,801 1,615,870 Joseph Keegan, Ph.D. 9,191,329 146,240 1,615,870”
Edward Chan resigned as Director at INTERPACE BIOSCIENCES, INC..
“On November 15, 2023, Edward Chan, a Class II director designated by 1315 Capital II, L.P. to the board of directors (the “ Board ”) of Interpace Biosciences, Inc. (the “ Company ”), provided notice to the Company of his resignation from the Board, effective immediately.”
INTERPACE BIOSCIENCES, INC. reported nine months ended September 30, 2023 results: revenue $29.9 million. Guidance reaffirmed.
“For the Nine Months Ended September 30, 2023 as Compared to the Nine Months Ended September 30, 2022 ● Net Revenue was $29.9 million, an increase of 27% from $23.5 million for the prior year”
INTERPACE BIOSCIENCES, INC. reported third quarter ended September 30, 2023 results: revenue $9.1 million. Guidance reaffirmed.
“in such filing. --- EX-99.1 () --- EX-99.1 2 ex99-1.htm Exhibit 99.1 Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results ● Q3 Revenue of $9.1 million; an 11% increase year-over-year ● Q3 Test volume up 11% year-over-year ● Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial contracts and”
INTERPACE BIOSCIENCES, INC. incurred credit facility of $2,500,000 with BroadOak Fund V, L.P. at 8.00% per annum.
“Second Amendment ”) with BroadOak Fund V, L.P. (“ BroadOak ”), pursuant to which, among other things, the Company and BroadOak agreed to: (i) a payment of a lump sum payment of $2,500,000 on or prior to October 31, 2023 in full satisfaction of the $3,000,0000 terminal payment under the Loan and Security Agreement, dated October 29, 2021, as amended by the First”
INTERPACE BIOSCIENCES, INC. amended Second Amendment to Loan Security Agreement with BroadOak Fund V, L.P. valued at $2,500,000 (effective 2023-10-24).
“On October 24, 2023, Interpace Biosciences, Inc. (the “ Company ”) and its subsidiaries entered into the Second Amendment to Loan Security Agreement (the “ Second Amendment ”) with BroadOak Fund V, L.P. (“ BroadOak ”), pursuant to which, among other things, the Company and BroadOak agreed to: (i) a payment of a lump sum payment of $2,500,000 on or prior to October 31, 2023 in full satisfaction of the $3,000,0000 terminal payment under the Loan and Security Agreement, dated October 29, 2021, as amended by the First Amendment to Loan and Security Agreement and Consent, dated May 5, 2022 (the “ Loan and Security Agreement ”); (ii) a reduction of the interest rate under the Loan and Security Agreement from nine percent (9.00%) per annum to eight percent (8.00%) per annum commencing on November 1, 2023 through October 31, 2024, or earlier, upon the occurrence of a change in control (the “ Maturity Date ”); and (iii) the Company’s right to extend the Maturity Date upon sixty (60) days’ writt”
INTERPACE BIOSCIENCES, INC. reported second quarter ended June 30, 2023 results: revenue Net Revenue was $11.0 million, net income Income from continuing operations was $0.4 million.
“Second quarter Net Revenue was $11.0 million, a $3.6 million increase over second quarter 2022. Income from continuing operations in the second quarter of 2023 was $0.4 million, an improvement of $2.5 million from the prior year quarter's loss of $2.1 million.”
Christopher McCarthy was appointed as Chief Financial Officer at INTERPACE BIOSCIENCES, INC..
“On July 24, 2023, the Board of Directors (the “ Board ”) of Interpace Biosciences, Inc. (the “ Company ”) appointed Christopher McCarthy, age 32, as Chief Financial Officer.”
INTERPACE BIOSCIENCES, INC. reported first quarter ended March 31, 2023 results: revenue $9.8 million.
“today announced financial results for the first quarter ended March 31, 2023 and provided a business and financial update. First quarter Net Revenue was $9.8 million.”
Christopher McCarthy was appointed as Principal Financial Officer at INTERPACE BIOSCIENCES, INC..
“On April 21, 2023, the Board of Directors of Interpace Biosciences, Inc. (the “Company”) appointed Christopher McCarthy, age 31, who has served as the Company’s Vice President of Finance and Enterprise Systems since August 2022, as Principal Financial Officer.”
INTERPACE BIOSCIENCES, INC. reported the fiscal year ended December 31, 2022 results: revenue $31.8 million.
“Net Revenue was $31.8 million for 2022, a 4% decrease over the prior year period.”
INTERPACE BIOSCIENCES, INC. reported the fourth quarter ended December 31, 2022 results: revenue $8.3 million.
“Net Revenue was $8.3 million, a decrease of 9% from $9.1 million for the prior year quarter.”
INTERPACE BIOSCIENCES, INC. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. at the 2022-11-10 meeting.
“V. Ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. For Against Abstain Broker Non-Votes 11,041,434 35,207 59,604 0”
INTERPACE BIOSCIENCES, INC. shareholders approved To grant the board of directors of the Company (the “Board”) discretionary authority to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of its common stock within the range of 1-for-2 to 1-for-10 with the exact ratio, if any, to be determined by the Boar at the 2022-11-10 meeting.
“IV. To grant the board of directors of the Company (the “Board”) discretionary authority to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of its common stock within the range of 1-for-2 to 1-for-10 with the exact ratio, if any, to be determined by the Board, but not later than one year after stockholder approval thereof. For Against Abstain Broker Non-Votes 10,270,993 800,853 64,399 0”
INTERPACE BIOSCIENCES, INC. shareholders approved Approval of the ESPP Amendment. at the 2022-11-10 meeting.
“III. Approval of the ESPP Amendment. For Against Abstain Broker Non-Votes 9,501,243 85,297 26,858 1,522,847”
INTERPACE BIOSCIENCES, INC. shareholders approved Approval of the Plan Amendment. at the 2022-11-10 meeting.
“II. Approval of the Plan Amendment. For Against Abstain Broker Non-Votes 9,498,523 88,097 26,778 1,522,847”
INTERPACE BIOSCIENCES, INC. shareholders approved Election of one Class I director to serve until the 2025 annual meeting or until such director's successor is duly elected and qualified. at the 2022-11-10 meeting.
“I. Election of one Class I director to serve until the 2025 annual meeting or until such director’s successor is duly elected and qualified. Name For Withhold Broker Non-Votes Stephen J. Sullivan 8,793,313 820,085 1,522,847”
INTERPACE BIOSCIENCES, INC. reported the quarter ended September 30, 2022 results: revenue $8.2 million.
“Announces Third Quarter 2022 Financial and Business Results Sale of Pharma Significantly Improves Liquidity Resulting in Removal of Going Concern ● Q3 Revenue of $8.2 million up 2% versus Prior Year ● Q3 Adjusted EBITDA Positive ● Cash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, November 14, 2022 (GLOBE NEWSWIRE)”
INTERPACE BIOSCIENCES, INC. amended Amendment with Saddle Lane Realty, LLC valued at $550,000 per year (effective 2022-10-31).
“On October 31, 2022, the Company entered into a fourth amendment (the “Amendment”) to its existing Pittsburgh laboratory lease (the “Lease”) for 20,000 leasable square feet of space located at 2515 Liberty Avenue, Pittsburgh, Pennsylvania with Saddle Lane Realty, LLC (the “Landlord”) to exercise the Company’s first option and right to extend the term of the Lease to June 30, 2028.”
Thomas Freeburg resigned as Chief Financial Officer at INTERPACE BIOSCIENCES, INC..
“On September 30, 2022 (the “Transition Date”), Thomas Freeburg, the Chief Financial Officer of Interpace Biosciences, Inc. ( the “Company”), resigned from his position as Chief Financial Officer and as an employee of the Company.”
Vijay Aggarwal was appointed as Director at INTERPACE BIOSCIENCES, INC..
“Dr. Vijay Aggarwal as a director to replace Mr. Lev on the Company's Board, effective February 1, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.